SciELO - Scientific Electronic Library Online

 
vol.41 número1Carcinoma tricofolicular con capacidad metastásica índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Cirugía Plástica Ibero-Latinoamericana

versão On-line ISSN 1989-2055versão impressa ISSN 0376-7892

Resumo

CASTANO-GONZALEZ, I.; VILAR-ALEJO, J.; FERNANDEZ-PALACIOS, J.  e  CARRETERO-HERNANDEZ, G.. Infliximab use as a therapeutic option in bilateral breast refractory postoperative pyoderma gangrenosum. Cir. plást. iberolatinoam. [online]. 2015, vol.41, n.1, pp.97-103. ISSN 1989-2055.  https://dx.doi.org/10.4321/S0376-78922015000100012.

Pyoderma gangrenosum is a rare, non-infection, ulcerating skin disease, included into neutrophilic dermatosis. The pathogenesis of pyoderma gangrenosum has not been determined yet, but it might be related to the immunologic mechanism. The breast localization is unusual, appearing after surgery in most of cases due to the phatergy phenomenon but it can also appear unexpectedly. We report a case of bilateral postsurgical pyoderma gangrenosum of the breast in a patient with breast cancer subjected to mastectomy with reconstruction. The case is wrongly diagnosed as surgical wound dehiscence leading to several debridements that exacerbate the problem and delay the diagnosis by more than one year. After several treatments, it was decided to start with infliximab therapy due to the refractoriness of the process, evolving satisfactorily. The aim of investigating this case is to be able to detect the disease early, to prevent physical and psychological harm.

Palavras-chave : Pyoderma gangrenosum; Breast surgery; Infliximab.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons